Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GRX1462
- Development stage
- Preclinical
- Lead developer
- Band Therapeutics
- Modality
- RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
GRX1462 is an experimental aptamer-toxin conjugate (ATC) being developed by Band Therapeutics (also known as Guardian Therapeutics) for the treatment of various cancers. It consists of a high-affinity nucleic acid aptamer that specifically targets the Human Epidermal Growth Factor Receptor 3 (HER3), a protein often overexpressed in solid tumors and associated with poor prognosis. The aptamer is conjugated to a cytotoxic toxin payload. Upon binding to HER3 on the surface of malignant cells, the conjugate is internalized via receptor-mediated endocytosis, delivering the toxin directly into the cell to induce apoptosis. This targeted delivery mechanism is intended to maximize anti-tumor activity while minimizing systemic side effects. The program is currently in the preclinical development stage.
- Other names
- Anti-HER3 aptamer toxin conjugateAnti-HER-3 aptamer toxin conjugateAnti-HER 3 aptamer toxin conjugate
02
Targets
ERBB3 (Erb-b2 receptor tyrosine kinase 3)
Beyond the preview
Go deeper on GRX1462.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GRX1462.